Cargando…
Reduced Neointima Formation After Arterial Injury in CD4−/− Mice Is Mediated by CD8(+)CD28(hi) T Cells
BACKGROUND: CD8(+) T‐cell activation, characterized by increased CD28 expression, reduces neointima formation after arterial injury in mice. The CD8(+)CD28(hi) phenotype is associated with increased effector function. In this study, we used a mouse model that has CD8(+) but no CD4(+) T cells (CD4−/−...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3698777/ https://www.ncbi.nlm.nih.gov/pubmed/23702879 http://dx.doi.org/10.1161/JAHA.113.000155 |
Sumario: | BACKGROUND: CD8(+) T‐cell activation, characterized by increased CD28 expression, reduces neointima formation after arterial injury in mice. The CD8(+)CD28(hi) phenotype is associated with increased effector function. In this study, we used a mouse model that has CD8(+) but no CD4(+) T cells (CD4−/−) to assess the role of CD8(+) T cells and test the function of CD8(+)CD28(hi) T cells in modulating neointima formation after arterial injury. METHODS AND RESULTS: Neointima formation after pericarotid arterial cuff injury was significantly less in CD4−/− mice compared with wild‐type (WT) mice. Negligible baseline lytic activity by splenic CD8(+) T cells from uninjured WT mice against target syngeneic smooth muscle cells was significantly increased 7 days after injury. Interestingly, CD8(+) T cells from uninjured CD4−/− mice had significant lytic activity at baseline that remained elevated 7 days after injury. CD8(+) T‐cell lytic activity was significantly reduced by depletion of CD28(hi) cells. CD8(+)CD28(hi) T cells adoptively transferred into recipient Rag‐1−/− mice significantly reduced neointima formation compared with CD8(+)CD28(+) T‐cell recipient mice. CONCLUSIONS: CD8(+) T cells reduced neointima formation after arterial injury, attributed in part to increased function of the CD8(+)CD28(hi) phenotype. |
---|